Fatty acids as determinants of in-vivo lipid peroxidation: The EFFGE study in Eastern Finnish hypertensive and non-hypertensive subjects

References

• Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev. 2008;7:558–66.
   PubMed Web of Science ®Google Scholar
• Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883–7.
   PubMed Web of Science ®Google Scholar
• Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal. 2010;12:1009–59.
   PubMed Web of Science ®Google Scholar
• Abbey M, Belling GB, Noakes M, Hirata F, Nestel PJ. Oxidation of low-density lipoproteins: intraindividual variability and the effect of dietary linoleate supplementation. Am J Clin Nutr. 1993;57:391–8.
   PubMed Web of Science ®Google Scholar
• Reaven P, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest. 1993;91:668–76.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.
   PubMed Web of Science ®Google Scholar
• Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation. 2009;119:902–7.
   PubMed Web of Science ®Google Scholar
• Astrup A, Dyerberg J, Elwood P, Hermansen K, Hu FB, Jakobsen MU, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?Am J Clin Nutr. 2011;93:684–8.
   PubMed Web of Science ®Google Scholar
• Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM. n-6 fatty acid- specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr. 2010;104:1586–600.
   PubMed Web of Science ®Google Scholar
• Pratico D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis. 2008;201:8–16.
   PubMed Web of Science ®Google Scholar
• Davis TA, Gao L, Yin H, Morrow JD, Porter NA. In vivo and in vitro lipid peroxidation of arachidonate esters: the effect of fish oil omega-3 lipids on product distribution. J Am Chem Soc. 2006;128:14897–904.
   PubMedGoogle Scholar
• Mas E, Woodman RJ, Burke V, Puddey IB, Beilin LJ, Durand T, et al. The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: results from two placebo-controlled interventions. Free Radic Res. 2010;44:983–90.
   PubMed Web of Science ®Google Scholar
• Musiek ES, Yin H, Milne GL, Morrow JD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids. 2005;40:987–94.
   PubMed Web of Science ®Google Scholar
• Tsikas D, Suchy MT, Niemann J, Tossios P, Schneider Y, Rothmann S, et al. Glutathione promotes prostaglandin H synthase (cyclooxygenase)-dependent formation of malondialdehyde and 15(S)-8-iso-prostaglandin F2alpha. FEBS Lett. 2012;586:3723–30.
   PubMedGoogle Scholar
• Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal. 2010; 13:145–56.
   PubMed Web of Science ®Google Scholar
• Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996; 271:8919–24.
   PubMed Web of Science ®Google Scholar
• Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res. 2009;50:716–22.
   PubMed Web of Science ®Google Scholar
• Shao B, Heinecke JW. HDL, lipid peroxidation, and atherosclerosis. J Lipid Res. 2009;50:599–601.
   PubMed Web of Science ®Google Scholar
• Yan Z, Mas E, Mori TA, Croft KD, Barden AE. A significant proportion of F2-isoprostanes in human urine are excreted as glucuronide conjugates. Anal Biochem. 2010;403:126–8.
   PubMed Web of Science ®Google Scholar
• Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434–9.
   PubMed Web of Science ®Google Scholar
• Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol. 2002;156:274–85.
   PubMed Web of Science ®Google Scholar
• Stojiljkovic MP, Lopes HF, Zhang D, Morrow JD, Goodfriend TL, Egan BM. Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster. J Hypertens. 2002;20:1215–21.
   PubMed Web of Science ®Google Scholar
• WMADeclaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (accessed 30 April 2013).
   Google Scholar
• Morrow JD, Roberts LJ. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol. 1999;300:3–12.
   PubMed Web of Science ®Google Scholar
• Nyyssönen K, Kaikkonen J, Salonen JT. Characterization and determinants of an electronegatively charged low-density lipoprotein in human plasma. Scand J Clin Lab Invest. 1996;56:681–9.
   PubMed Web of Science ®Google Scholar
• National Public Health Institute, Nutrition Unit. Fineli. Finnish food composition database. Release 7. Helsinki 2007. Available at: http://www.fineli.fi (accessed 4 February 2013).
   Google Scholar
• Pietinen P, Hartman AM, Haapa E, Rasanen L, Haapakoski J, Palmgren J, et al. Reproducibility and validity of dietary assessment instruments. II. A qualitative food frequency questionnaire. Am J Epidemiol. 1988;128:667–76.
   PubMed Web of Science ®Google Scholar
• Thurnham DI, Smith E, Flora PS. Concurrent liquid-chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem. 1988;34:377–81.
   PubMed Web of Science ®Google Scholar
• Ala-Kopsala M, Magga J, Peuhkurinen K, Leipälä J, Ruskoaho H, Leppäluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004;50:1576–88.
   PubMed Web of Science ®Google Scholar
• Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013;346:e8707.
   PubMed Web of Science ®Google Scholar
• Calder PC. Old study sheds new light on the fatty acids and cardiovascular health debate. BMJ. 2013;346:f493.
   Google Scholar
• Davies SS, Roberts LJ. F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med. 2011;50:559–66.
   PubMed Web of Science ®Google Scholar
• Moilanen T, Räsänen L, Viikari J, Åkerblom HK, Ahola M, Uhari M, et al. Fatty acid composition of serum cholesteryl esters in 3- to 18-year-old Finnish children and its relation to diet. Am J Clin Nutr. 1985;42:708–13.
   PubMed Web of Science ®Google Scholar
• Mori TA, Puddey IB, Burke V, Croft KD, Dunstan DW, Rivera JH, et al. Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox Rep. 2000;5:45–6.
   PubMed Web of Science ®Google Scholar
• Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003;35:772–81.
   PubMed Web of Science ®Google Scholar
• Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 2013;11:298–300.
   Google Scholar
• Collins P. Clinical cardiovascular studies of hormone replacement therapy. Am J Cardiol. 2002;90:30F–4F.
   PubMed Web of Science ®Google Scholar
• Mikkilä V, Räsänen L, Laaksonen MM, Juonala M, Viikari J, Pietinen P, et al. Long-term dietary patterns and carotid artery intima media thickness: the Cardiovascular Risk in Young Finns Study. Br J Nutr. 2009;102:1507–12.
   PubMedGoogle Scholar
• Hermenegildo C, Oviedo PJ, Laguna A, Garcia-Perez MA, Tarin JJ, Cano A. Transdermal estradiol reduces F2alpha-isoprostane levels in postmenopausal women. Menopause. 2008;15:714–17.
   PubMedGoogle Scholar
• Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004;109:843–8.
   PubMed Web of Science ®Google Scholar
• Nonaka-Sarukawa M, Yamamoto K, Aoki H, Takano H, Katsuki T, Ikeda U, et al. Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart. 2003;89:871–4.
   PubMed Web of Science ®Google Scholar
• Kaikkonen J, Porkkala-Sarataho E, Tuomainen TP, Nyyssönen K, Kosonen L, Ristonmaa U, et al. Exhaustive exercise increases plasma/serum total oxidation resistance in moderately trained men and women, whereas their VLDL + LDL lipoprotein fraction is more susceptible to oxidation. Scand J Clin Lab Invest. 2002;62:599–607.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ. Systematic review on the association between F2-isoprostanes and cardiovascular disease. Ann Clin Biochem. 2013; 50(Pt 2):108–14.
   PubMedGoogle Scholar
• Il’yasova D, Spasojevic I, Base K, Zhang H, Wang F, Young SP, et al. Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes. Diabetes Care. 2012;35:173–4.
   PubMed Web of Science ®Google Scholar
• Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med. 2004;36:226–32.
   PubMed Web of Science ®Google Scholar
• Woodward M, Croft KD, Mori TA, Headlam H, Wang XS, Suarna C, et al. Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin Sci (Lond). 2009;116:53–60.
   PubMedGoogle Scholar
• Martinelli N, Girelli D, Malerba G, Guarini P, Illig T, Trabetti E, et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr. 2008; 88:941–9.
   PubMed Web of Science ®Google Scholar
• Gueraud F, Atalay M, Bresgen N, Cipak A, Eckl PM, Huc L, et al. Chemistry and biochemistry of lipid peroxidation products. Free Radic Res. 2010;44:1098–124.
   PubMed Web of Science ®Google Scholar